Table 2.
Baseline disease characteristics
| Placebo (N = 131) | Abrocitinib 100 mg QD (N = 238) | Abrocitinib 200 mg QD (N = 226) | Dupilumab 300 mg Q2W (N = 242) | |
|---|---|---|---|---|
| Duration of AD, years, mean (SD) | 21.4 (14.4) | 22.7 (16.3) | 23.4 (15.6) | 22.8 (14.8) |
| IGAa, n (%) | ||||
| Moderate | 88 (67.2) | 153 (64.3) | 138 (61.1) | 162 (66.9) |
| Severe | 43 (32.8) | 85 (35.7) | 88 (38.9) | 80 (33.1) |
| %BSA affected, mean (SD) | 48.9 (24.9) | 48.1 (23.1) | 50.8 (23.0) | 46.5 (22.1) |
| EASIb, mean (SD) | 31.0 (12.6) | 30.3 (13.5) | 32.1 (13.1) | 30.4 (12.0) |
| Head and neck (max 7.2) | 3.0 (1.6) | 2.8 (1.7) | 2.9 (1.6) | 2.9 (1.6) |
| Trunk (max 21.6) | 8.9 (4.6) | 8.4 (4.5) | 9.1 (4.7) | 8.5 (4.9) |
| Upper limbs (max 14.4) | 7.1 (3.0) | 6.8 (3.3) | 7.3 (3.3) | 6.8 (2.9) |
| Lower limbs (max 28.8) | 11.8 (6.8) | 12.3 (7.2) | 12.7 (6.6) | 12.0 (6.1) |
| SCORADc, mean (SD) | 67.9 (12.0) | 66.8 (13.8) | 69.3 (12.7) | 67.9 (11.4) |
AD Atopic dermatitis, BSA body surface area, EASI Eczema Area and Severity Index, IGA Investigator’s Global Assessment, max maximum, SCORAD SCORing Atopic Dermatitis
aIGA ranges from clear (0) to severe (4)
bEASI total score ranges from 0 to 72, with higher scores indicating more severe disease. The scalp, palms, and soles were not assessed in this study
cSCORAD total score ranges from 0 to 103, with higher scores representing more severe disease